The Pharma Data

AUGUST 5, 2020

vs 0.25) in ASCLEPIOS I and II, respectively ( P < 001 in both studies) (primary endpoints) 1. Showed a relative risk reduction of 34% ( P =.002) 002) in 3-month confirmed disability worsening (CDW) and 32% ( P =.01) Ofatumumab was originally developed by Genmab and licensed to GlaxoSmithKline. vs 0.22) and 58% (0.10

Trials 52

Trials Medicine Production Containment 52

Roots Analysis

FEBRUARY 22, 2022

Notable examples of other autoinjector-based combination products include Fasenra® Pen (AstraZeneca), Gvoke® Hypopen (Xeris Pharmaceuticals), NUCALA Autoinjector (GlaxoSmithKline), and Vyleesi Autoinjector (AMAG Pharmaceuticals® / Palatin Technologies). The generic version of EpiPen received the FDA approval in 2018.

Drug Delivery 52

Drug Delivery Production Marketing Development 52

The Pharma Data

MAY 5, 2021

GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous and subcutaneous BENLYSTA (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis (LN) in Europe, in addition to systemic lupus erythematosus (SLE).

Medicine 52

Medicine Scientist Production Vaccination 52

The Pharma Data

MAY 7, 2021

Review will support a formal Marketing Authorisation Application. GlaxoSmithKline plc and Vir Biotechnology, Inc. The rolling review will continue until enough evidence is available to support a formal marketing authorisation application. About the COMET-ICE Study Design.

Antibody 52

Antibody Trials Vaccination Vaccine 52

The Pharma Data

MARCH 26, 2021

GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced the submission of an application to the U.S. Data from the registrational COMET-ICE trial also will form the basis for a Biologics License Application (BLA) submission to the FDA.

Antibody 52

Antibody Trials Vaccination Vaccine 52

Delveinsight

AUGUST 13, 2020

GlaxoSmithKline’s Trelegy Ellipta for the treatment of Inadequately Controlled Asthma. GlaxoSmithKline is worth mentioning here, as it is presenting key posters and studies on Trelegy Ellipta in uncontrolled asthma patients.

Antibody 40

Antibody Medicine Trials Development 40

XTalks

SEPTEMBER 14, 2020

For example, the S&P 500 is just 100 points below its pre-pandemic peak while NASDAQ had fully recovered its losses by early June and is now reporting record highs. percent of applicants have apparently been defrauding the program by “double-dipping”, a no-no that the federal government is threatening to punish. billion in June.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92